Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori

Pfizer’s aging Xalkori is the drug to beat in ALK-positive non-small cell lung cancer. After showing Alunbrig cut the risk of disease progression by 51% compared with Xalkori at the two-year mark, Takeda is preparing for regulatory submissions in the first-line setting.